Código QR (código de barras bidimensional)

Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer

No evidence is available on the head-to-head comparison of clinical outcomes of patients treated with immune checkpoint inhibitors (ICIs) for advanced non-small cell lung cancer (NSCLC) in a real-world setting. We aimed to compare the effectiveness and cost-effectiveness profile of nivolumab, pembro...

Fuld beskrivelse

Na minha lista:
Principais autores: Matteo Franchi, Giacomo Pellegrini, Giovanni Corrao
Format: Artigo
Sprog:Inglês
Udgivet: MDPI AG 2022-04-01
Serier:Pharmaceuticals
Fag:
non-small cell lung cancer
immune checkpoint inhibitors
real-world
effectiveness
cost-effectiveness
Online adgang:https://www.mdpi.com/1424-8247/15/4/489
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker